Palvella Therapeutics, Inc (PVLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.23B
Last updated: Nov 17, 2026 at 11:05 AM ET
Palvella Therapeutics, Inc (PVLA) Stock Forecast
Analysts expect Palvella Therapeutics (PVLA) to earn -$5.98 per share in the fiscal year ending Dec 31, 2026. Of 16 analysts, 16 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 16 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$5.98
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$7.77
- EPS consensus, revenue $20.56M
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$5.98 | -$6.40 to -$4.87 | 9 | N/A | N/A | 15 |
| Dec 31, 2027 | -$7.77 | -$13.52 to -$3.58 | 11 | $20.56M | $6.50M to $53.61M | 14 |
Quarterly Estimates
The EPS consensus rises from -$2.15 for the quarter ending Dec 31, 2026 to -$2.07 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.15 | -$2.68 to -$1.72 | 17 |
| Mar 31, 2027 | -$2.07 | -$2.40 to -$1.70 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.37.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.98 | -$6.39 | -$6.42 | -$6.37 | -$6.37 | N/A |
| Fiscal year ending Dec 31, 2027 | -$7.77 | -$7.91 | -$7.50 | -$7.50 | -$7.50 | N/A |
| Quarter ending Mar 31, 2027 | -$2.07 | -$2.18 | -$2.27 | -$2.27 | -$2.27 | N/A |
Frequently Asked Questions About PVLA
What is the PVLA stock forecast?
Consensus analyst estimates put Palvella Therapeutics's EPS at -$5.98 for the fiscal year ending Dec 31, 2026. The consensus rating from 16 analysts is Buy.
How do analysts rate PVLA stock?
Of 16 analysts covering Palvella Therapeutics, 0 rate it Strong Buy, 16 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PVLA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.98, with estimates from -$6.40 to -$4.87 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$7.77, with estimates from -$13.52 to -$3.58 from 11 analysts.
What revenue do analysts expect from Palvella Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.56M, with estimates from $6.50M to $53.61M.
How many analysts cover PVLA?
16 analysts rate Palvella Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PVLA pages: Overview, Earnings, Forecast, Financials, Competitors